In prostate cancer cells, for instance, TGF-β therapy leads to nuclear accumulation of MAPK1, which in turn promotes cancer cell EMT and upregulates the production of MMP1, MMP2/9, and MMP9 [43]. The gene discussed is MMP1; the disease is prostate carcinoma.